First report of CTX-M-14 producing clinical isolates of Salmonella serovar Typhimurium from Egypt.

Salmonella serovar Typhimurium is a leading cause of food-borne diseases worldwide. Its ability to acquire new antibiotic resistance mechanisms is of increasing therapeutic concern [1]. CTX-M betalactamases are the most common extended spectrum β-lactamases (ESBLs) worldwide [2]. The first report of CTX-M detection in Salmonella was in a Tunisian outbreak caused by Salmonella enterica serovar Wein (S. Wein) in 1988 [3]. We report acquisition of the CTX-M-14 ESBL by three pediatric isolates of S. Typhimurium from Egypt. To our knowledge this is the first report of CTX-M-producing Salmonella in Egypt. Three pediatric isolates 68, 94, and 111, serologically confirmed as S. Typhimurium, were shown to be resistant to cefotaxime and ceftriaxone [minimum inhibitory concentration (MIC) > 128 μg/ml, Table 1]. Ceftazidime MICs varied from 8 μg/ml (susceptible) to 32 μg/ml (resistant), and all isolates were ESBL-positive by the Clinical and